الفهرس 
Sterold componets of gynera
ResultsOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
In the present study 4 hae.oetatio parameters were
investigated in SO women receiving Gynera pille monthly for 6
months for birth control. All WOman were clinically h8althy,
in the reproductive ag~, ~exually active, non lactating, have
at leBst one normal menBtrual cycle B~nce terminat10n of
there Ift~t pregnancy, must rely exclusively upon pills c.~
the’ onl::ymethod of contr6ception t.hrough t.he courae of lIt.udy
and the lHat pregnancy tar~inated at lea~t.42 daya prio~ to
admes~ion t.o the study.
TO study the ri6k of venDue thromboeie in this group the
following parameters were a6~e~sad entithrombin Ill, platelet
count, bleeding time and clotting time.
The reoultB obtained aftor 3 and 6 months of UBe of
Gynera llIiI:rtI compared with the pretreatment ValUl’lB and the
tollowinq re5ultg _~& reportQd.
1- No significant change WI1l.IIl dBtected in ant~throl’lbin III
lE1VE11s aftllir 3 and 6 mcnthM of use of Gyn8:r1l..
2- .No siqnific.!l.nctha.n,.’_!!8’ det.ected i’n platelet count after
3 and 6 months of use of Gynera.
3- Mo significant change W!aB detected in bleeding time after
3 and 6 month!> of use of Gynera.
4- No 15iqnif ic.ant change W8S detected in c~o’t.tinqtime after
3 and 6 months of use of Gynera.
The eV61uated lo£luences of u~e 9f Gynera on plasma
antithrombin lIl, platelet count, bleeding time and clotting
time proved their relative safety regarding the risk of
thromboslB. Howev9r, the risk of thro.bo~i8 can not be ruled
out because the markers applied do not H~~e88 the multiple
key variables which regulate coagulation and fibrinolyBi$.